Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720

Vaccine

Volumn 15, Issue 2, 1997, Pages 176-178

  Lawrence, Gregor W ^a   Saul, Allan ^a   Giddy, Andrew J ^b   Kemp, Richard ^c   Pye, David ^d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Roche Products Pty Ltd   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 720; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALARIA VACCINES; MALE; MANNITOL; MIDDLE AGED; OILS; OLEIC ACIDS;

EID: 0031081785     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00150-8     Document Type: Article

References (4)

1. 1 Gupta, R.K., Relyveld, E.H., Lindbland, E.B., Bizzini, B., Ben-Efraim, S. and Gupta, C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293-306
2. 2 Gordon, D.M. Use of novel adjuvants and delivery systems to improve the humoral and cellular response to malaria vaccine candidate antigens. Vaccine 1993, 11, 591-593
3. 3 Collins, W.E., Pye, D., Crewther, P.E. et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen 1 of Plasmodium fragile. Am J. Trop. Med. Hyg. 1994, 51, 711-719
4. 4 Scalzo, A.A., Elliott, S.L., Cox, J., Gardner, J., Moss, D.J. and Suhrbier, A. Induction of protective cytotoxic T cells to murine cytomegalovirus using a nonapeptide and a human compatible adjuvant (MONTANIDE ISA 720). J. Virol. 1995, 69, 1306-1309